China ’s crackdown on business bribery in the field of pharmaceutical purchasing and sales has continued to increase.A number of public hospitals in China have been dismissed, and some companies involved pay doctors to pay 40 % of the purchase price of near -drug purchases.
According to the Huaxia Times, the State Administration of Market Supervision of China has announced five typical cases of anti -improper competition special law enforcement actions, which focuses on two commercial bribes of the medical and health industry.
Some companies are transporting illegal benefits in the name of sponsoring scientific research funds and academic conference fees.Some of them pay for the hospital staff in the medical purchase and sales session; some are set up to collect funds for bribery through the production session that they can be used to pick up the price of drug prices and false transactions in circulation.
A typical case involving drug rebates show that Hangzhou Jianning Pharmaceutical Technology Co., Ltd. has agreed to obtain drug promotion commissions for drug production enterprises.Responsible for the operation of a pharmaceutical injection and a capsule into the hospital and continuously purchased, and pay Wang Mou's rebate at a certain percentage of the drug procurement price of the hospital.
From June 14, 2015 to June 14, 2019, through the operation of Wang, the hospital purchased a total of 28924 pockets for a certain injection of drugs and 6,760 boxes of a capsule., S $ 712,900).Hangzhou Jianning Pharmaceutical Technology Co., Ltd. paid a return deduction of 1.4481 million yuan to Wang through employees, close to 40 % of the purchase price of drugs.
Zhou Shu, a strategic consultant of the pharmaceutical industry, believes that the General Administration of Market Supervision reports the information of the two pharmaceutical business bribery cases, whether it is to use the payback rebate of the staff of the hospital, or use a more hidden way in the circulation link.The bribery of funds will be severely hit.
The Chinese regulatory authorities increased the special rectification of commercial bribery in the field of medical and health in 2022, and set off multiple rounds of medical anti -corruption storms in various places.From September to December, the special rectification of commercial bribery and medical prices in the fields of medical and health in Shanxi, Beijing, Henan and other places has also announced new progress.
According to incomplete statistics, since the end of October alone, the dean and party secretary of the 10 public hospitals have been dismissed. Except for one person's illegal cause, they have been identified and the procuratorial organs are transferred to the procuratorial organs.Accept disciplinary review and supervision investigation.
